Labcorp announced the nationwide availability of ColoSense, an RNA-based at-home screening test for colorectal cancer approved by the Food and Drug Administration (FDA). Offered through a commercial collaboration with test developer Geneoscopy, the test expands Labcorp’s range of colorectal cancer screening solutions. The test is now covered for eligible Medicare and Medicare Advantage beneficiaries following an update to the National Coverage Determination by the Centers for Medicare & Medicaid Services in June, with additional commercial coverage also available…
